Efficacy of RTS,S malaria vaccine given with EPI vaccines

The Lancet Infectious Diseases

Volumn 11, Issue 10, 2011, Pages 722-723

  Dicko, Alassane ^a   Doumbo, Ogobara ^a  

^a UNIVERSITY OF BAMAKO   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE;

CHILDHOOD DISEASE; GHANA; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALARIA FALCIPARUM; MORBIDITY; NONHUMAN; NOTE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TANZANIA; YEAST CELL;

EID: 80053293366     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70186-4     Document Type: Letter

References (12)

1. World Malaria Report WHO, (accessed June 27, 2011). http://libdoc.who.int/publications/2009/9789241563901_eng.pdf.
2. Cissé B, Sokhna C, Boulanger D, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006, 367:659-667.
3. Dicko A, Sagara I, Sissoko MS, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 2008, 7:123.
4. Kweku M, Liu D, Adjuik M, et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS One 2008, 3:e4000.
5. Dicko A, Diallo AI, Tembine I, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011, 8:e1000407.
6. Konaté AT, Yaro JB, Ouédraogo ZA, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide treated bednet in Burkina Faso: a randomized, double blind, placebo-controlled trial. PLoS Med 2011, 8:e10004008.
7. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358:1927-1934.
8. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366:2012-2018.
9. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521-2532.
10. Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008, 359:2599-2601.
11. Agnandji ST, Asante KP, Lyimo J, et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the Expanded Program of Immunization. J Infect Dis 2010, 202:1076-1087.
12. Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, published online July 21. 10.1016/S1473-3099(11)70100-1.